Clinical aspects of Parkinson's disease

 

Definition

 

A slowly progressive loss of dopamine cells in the substantia nigra causing bradykinesia (slowness of movement with progressive reduction of speed and amplitude of repetitive voluntary movement) or rest tremor or both. Muscular rigidity and a degree of postural imbalance are common features A diagnosis of  possible Parkinson's disease can be made if bradyinesia or rest tremor are present, and if the following features are absent (history of repeated stroke head injury or encephalitis, toxin exposure (manganese, MPTP) neuroleptic therapy oculogyric crises, supranuclear  gaze palsy, pyramidal or cerebellar signs, early severe autonomic involvement or dementia CT scan showing tumour, hydrocephalus or basal ganglia calification, spontaineous remission, failure of akinesia to respond to large doses of 1-dopa). Probable Parkinson's disease also requires an asymmetrical, wide-amplitude rest tremor for 6 months or two of the following: excellent response (70-100%) to l-dopa, swings in motor function related to l-dopa doses, severe I-dopa induced chorea, l-dopa response for 5 years, clinical course of 10 years.

 

Epidemiology

 

Parkinson's disease has a sporadic worldwide occurrence with no classical Mendelian inheritance of the usual form. A family history is obtained in 15% of patients, occasionally 2 or more family members can be found to have the disease, and there are rare large kindreds with autosomal dominant disease imitating the sporadic form apart from an earlier age of onset, a more rapid disease progression, and in some kindreds a predominance of associated dementia. The prevalence of sporadic Parkinson's disease in the UK and USA is approximately 1601100,000, but in China, Japan and Nigeria prevalence may be lower at 45-80 /100,000. The disease may begin after the age of 20 but is rare before 30 years, and is  rare beforev30 years and is increasingly common with age affecting up to 2% of the population aged ove 80 years. Men and women are equally affected. Patients are less likely to have smoked before disease onset than the general population Patients are also said to have been more introspective than unaffected twins or siblings, but there is some, controversy as to how robust this observation is.

 

Pathophysiology

 

In addition to the substantia nigra, the distribution of neuronal loss in the nervous system affects other specific populations in a highly selective fashion. These are the locus coeruleus, nucleus basalis of Mynert, thalamus, raphe nuclei, limbic cortex and neocortex, and the entire autonomic nervous system. Neural degeneration is also associated, invariably with the formation of intracytoplasmic neuronal inclusions called Lewy bodies, in some of the neurones. In addition to Parkinson's disease, it can therefore be predicted that disease in these other regions may produce symptoms. In particular, loss of the cholinergic innervation of the cerebral cortex  from the nucleus basalis of Meynert, and pathology in the cerebral cortex itself, may Predispose to dementia.

 

Clinical features

 

The condition usually presents insidiously with development of rest tremor of one arm, alternatively stiffness in an arm with slowness and difficulty with moving such as turning over in bed dressing, eating and swallowing  Sometimes the onset is associated with acute physical or emotional stress, and a period of weeks or months of remission may then occur after stress has been alleviated, only tor the presenting symptoms to return again. The presentation may be complicated by prodromal features of anxiety, and possibly depression and lethargy. The classic clinical criteria are said to be rest tremor, bradykinesia, muscular rigidity and postural instability. Bradykinesia affects many bodily functions, producing a masked face, slowness in eating, micrographia, a short step and shuffling gait, and loss of associated movements. Muscular rigidity often causes stiffness, classically a frozen shoulder, and together with akinesia this symptom may cause pain. Early postural instability responds to therapy, and is mild  Late in disease, particularly in the elderly, postural instability is intractable and profound.

 

Dementia is rare before age 60 years, but thereafter becomes increasingly common. In the 80s the risk of dementia over 5 years is 50 % compared with a figure of approximately 20% in the population for demential/Alzheimer's disease.

 

Investigations

 

No abnormalities are found on routine investigation of Parkinson's disease. It may be appropriate to measure thyroid function, serum calcium, syphilis serology, and have a CT scan.

 

Differential diagnoses

 

Anxiety, essential tremor, other parkinsonian disorders such as drug induced, striatiatonigral degeneration and Steele-Richardson~Olszewski disease. Uncommon toxic causes are MPTP, carbon monoxide, cyanide, carbon disulphide, manganese. Other causes are chronic trauma (pugilistic encephalopathy) and brain tumours.

 

Treatment

 

The mainstay of treatment remains I-dopa therapy, combined with a dopa-decarboxylase inhibitor. However, it can be argued that approximately 60-70 years divides patients into younger and older onset in relation to therapy. In view of the fact that patients maintained on l-dopa therapy will invariably develop profoundly troublesome motor fluctuations after 10-15 years can be treated initially with levodopa sparing agents such as amantadine, direct acting dopamine agonists (bromocriptine/pergolide) or possibly an anti-cholinergic drug. One or more of these ca n be used. Where additional treatment is required madopar or sinemet, preferably in a slow release formulation can be added. For older onset patients treatment should be initiated with madopar or sinemet, increasing quickly to a modest twice daily dose. In this older age group other therapies, which are more likely to produce side effects, should be avoided.